Does Dr. MARY ADEBOWALE have financial conflicts of interest?

Dr. MARY ADEBOWALE (MD) has received a total of $1,006 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $1,006 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MARY ADEBOWALE?

According to CMS Open Payments data, Dr. MARY ADEBOWALE received funding from OTSUKA AMERICA PHARMACEUTICAL ($241), E.R. SQUIBB & SONS, L.L.C ($133), and ASTELLAS PHARMA US ($125).

Does Dr. MARY ADEBOWALE receive research grants or speaking fees?

Dr. MARY ADEBOWALE has received $1,006 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MARY ADEBOWALE

MDReal-Time Hydrated

Specialty: Student in an Organized Health Care Education/Training Program

Practice Location: HOLLYWOOD, MD 20636

NPI Number: 1508423351

LIFETIME INDUSTRY VALUE

$1,006

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ADEBOWALE is a verified Student in an Organized Health Care Education/Training Program practitioner based in HOLLYWOOD, MD.

Between 2021 and 2024, Dr. ADEBOWALE had an overall industry promotional and research financial footprint of $1,006 as recorded in the federal CMS Open Payments database.

$1,006 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ADEBOWALE's primary funding source is OTSUKA AMERICA PHARMACEUTICAL, which accounts for $241 (representing 24% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

OTSUKA AMERICA PHARMACEUTICAL

Rank 1

$241

24%

E.R. SQUIBB & SONS, L.L.C

Rank 2

$133

13.2%

ASTELLAS PHARMA US

Rank 3

$125

12.4%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.